MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...
EST Ocugen (OCGN) files to sell 57.54M shares of common stock for holdersInvest with Confidence: Follow TipRanks' Top Wall Street ...
Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.73 which represents a decrease of $-0.05 or -6.41% from the prior close of $0.78. The stock opened at $0.78 and touched a low of $0.71 ...
This was the stock's second consecutive day of gains.
The stock's fall snapped a two-day winning streak.
Hosted on MSN11mon
Ocugen (OCGN) Price Target Increased by 58.33% to 6.46The average one-year price target for Ocugen (NasdaqCM:OCGN) has been revised to 6.46 / share.This is an increase of 58.33% from the prior estimate of 4.08 dated January 16, 2024. The price target ...
Maxim Group analyst Michael Okunewitch has maintained their bullish stance on OCGN stock, giving a Buy rating on January 13.Invest with ...
OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in ...
At close: 14 November at 4:00 pm GMT-5 ...
Jan. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies ...
Jan. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback